- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer
December 12th 2025, 12:28am
San Antonio Breast Cancer Symposium
Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.
Alpelisib Plus Fulvestrant Hits Primary PFS End Point in CDK4/6 Inhibitor–Pretreated, PIK3CA-Mutant, HR+/HER2– Breast Cancer
December 12th 2025, 12:16am
San Antonio Breast Cancer Symposium
Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.
CAPItello-291 Analysis Reveals Potential Utility of PIK3CA/AKT1/PTEN Alteration Detection Via ctDNA in Advanced HR+ Breast Cancer
December 11th 2025, 11:25pm
San Antonio Breast Cancer Symposium
Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.
Less Invasive Axillary Staging Yields Noninferior 3-Year Axillary RFS vs ALND in Node-Negative Breast Cancer
December 11th 2025, 10:57pm
San Antonio Breast Cancer Symposium
Axillary RFS at 3 years was noninferior with less vs more invasive staging procedures in node-negative breast cancer after neoadjuvant chemotherapy.
Oral and Subcutaneous Azacitidine Show Comparable PK, Safety Profiles in MDS and CMML
December 11th 2025, 10:36pm
ASH Annual Meeting and Exposition
Oral azacitidine demonstrated a similar pharmacokinetic and safety profile to the subcutaneous formulation in MDS or CMML.
Dr Punie on Patient-Reported Outcomes With Sacituzumab Govitecan vs Chemotherapy in Advanced TNBC
December 11th 2025, 9:21pm
San Antonio Breast Cancer Symposium
Kevin Punie, MD, discusses PRO data from the phase 3 ASCENT-03 trial.
Dr Rugo on Elacestrant-Based Combos in ER+/HER2– Locally Advanced or Metastatic Breast Cancer
December 11th 2025, 5:52pm
San Antonio Breast Cancer Symposium
Hope S. Rugo, MD, discusses an open-label umbrella study evaluating elacestrant in combination with everolimus or abemaciclib in ER-positive/HER2-negative advanced breast cancer.
Resection of MRI-Detected Disease Fails to Improve Recurrence Rates in Early Breast Cancer
December 11th 2025, 5:21pm
San Antonio Breast Cancer Symposium
Locoregional recurrence-free rates were similar in newly diagnosed breast cancer, irrespective of resection of MRI-detected disease.
Pembrolizumab Plus Radiation Yields Improvements in T-Cell Infiltration in Early Breast Cancer
December 11th 2025, 4:45pm
San Antonio Breast Cancer Symposium
Patients with early breast cancer who received pembrolizumab plus radiation therapy experienced significant improvements in T-Cell infiltration and promising pCR rates.
T-DXd Displays iDFS Benefit in Key Subgroups of HER2+ Early Breast Cancer With Residual Invasive Disease
December 11th 2025, 3:10am
San Antonio Breast Cancer Symposium
T-DXd yielded iDFS improvements in HER2-positive early breast cancer with residual invasive disease, irrespective of HER2 expression of neoadjuvant chemotherapy type.
Maintenance Tucatinib Plus HP Extends Median PFS Beyond 2 Years in Advanced HER2+ Breast Cancer
December 11th 2025, 2:38am
San Antonio Breast Cancer Symposium
Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.
Dr Alkassis on Cathepsin Protease Expression and Its OS Association With T-DXd in Metastatic Breast Cancer
December 11th 2025, 12:53am
San Antonio Breast Cancer Symposium
Samer Alkassis, MD, PhD, discusses how cathepsin protease expression may correlate with survival outcomes to trastuzumab deruxtecan in metastatic breast cancer.
Trastuzumab Deruxtecan Plus Pertuzumab Does Not Worsen QOL in HER2+ Metastatic Breast Cancer
December 10th 2025, 10:55pm
San Antonio Breast Cancer Symposium
Frontline treatment with T-DXd plus pertuzumab improved QOL vs THP in patients with HER2-positive advanced or metastatic breast cancer.
Nuvisertib Plus Momelotinib Is Safe, Produces Spleen, Symptom, Anemia Responses in R/R Myelofibrosis
December 10th 2025, 10:51pm
ASH Annual Meeting and Exposition
Nuvisertib demonstrated clinical activity as both a single agent and in combination with momelotinib for patients with relapsed/refractory myelofibrosis.
Dr Hamilton on First-Line Tucatinib-Based Maintenance in HER2+ Metastatic Breast Cancer
December 10th 2025, 10:34pm
San Antonio Breast Cancer Symposium
Erika P. Hamilton, MD, discusses data from HER2CLIMB-05 evaluating tucatinib plus trastuzumab/pertuzumab first-line maintenance in HER2-positive breast cancer.
Sacituzumab Govitecan Maintains QOL Benefit Over Chemotherapy in Previously Untreated TNBC
December 10th 2025, 10:19pm
San Antonio Breast Cancer Symposium
PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.
Sacituzumab Govitecan Fails to Meet Primary PFS End Point in First-Line HR+/HER2– mBC
December 10th 2025, 10:02pm
San Antonio Breast Cancer Symposium
Sacituzumab govitecan did not improve PFS per BICR vs chemotherapy after endocrine therapy in hormone-receptor–positive/HER2-negative breast cancer.
Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer
December 10th 2025, 9:55pm
San Antonio Breast Cancer Symposium
Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.
Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer
December 10th 2025, 9:34pm
San Antonio Breast Cancer Symposium
The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.
Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML
December 10th 2025, 8:05pm
ASH Annual Meeting and Exposition
Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.